Last reviewed · How we verify

NCT05408936: SGLT2HgB

SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers

Active, enrolled Last updated 14 May 2024
What this trial tests

trial testing SGLT2 inhibitor in Diabetes Mellitus, Type 2 in 80 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
3 June 2022
Primary endpoint
1 December 2023
1 June 2024

Quick facts

Lead sponsorUniversity of Patras
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment80
Start date3 June 2022
Primary completion1 December 2023
Estimated completion1 June 2024
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

University of Patras

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study of the response to SGLT2 inhibitors in type 2 diabetic patients with relevance to the erythropoesis and indexes of cardiorenal function. The study enrolls type 2 diabetic patients in whom the introduction of a SGLT2 inhibitor is deemed necessary as part of their routine treatment during their visit to our outpatient diabetes unit. A whole blood, a serum and a urine sample is obtained before and one month after the initiation of treatment with a SGLT2 inhibitor.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Mechanisms of diabetic cardiomyopathy: Focus on inflammation.
    Bellemare M, Bourcier L, Iglesies-Grau J, Boulet J, et al · · 2025 · cited 20× · PMID 39930551 · DOI 10.1111/dom.16242

Verify or expand the search:

Other trials of SGLT2 inhibitor

Trials testing the same drug.

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

Other University of Patras trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05408936.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing